|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
NeurAxon Announces $32 Million Series B Venture Capital Financing
September 3rd, 2007 No comments
NeurAxon Inc., a developer of next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), announced recently that it has closed a $32 million Series B Financing. The financing was led by new investors, Delphi Ventures and OrbiMed Advisors, LLC. Also participating in the round were Series A investors BDC Venture Capital, Genesys Capital Partners, H.I.G. Ventures, NeuroVentures Fund, Ventures West Capital Ltd. and new investor Lawrence E. Bloch, M.D., J.D., CEO of NeurAxon. Concurrent with the financing, Deepa Pakianathan, Ph.D., general partner of Delphi Ventures and Samuel P. Wertheimer, Ph.D., principal of OrbiMed Advisors, LLC have been appointed to the NeurAxon Board of Directors.
We believe that this substantial round of funding from blue-chip life science venture capital investors is a reflection of the strong potential of our proprietary nNOS therapeutic platform. NeurAxon has generated a portfolio of next generation pain therapeutics targeting nNOS, and the Series B proceeds will be used to accelerate the clinical development of our product candidates, commented Lawrence E. Bloch, M.D., J.D., Chief Executive Officer and Director of NeurAxon. On behalf of our current Board members, I am very pleased to welcome Drs. Pakianathan and Wertheimer to our Board of Directors and look forward to leveraging their experience and contributions as we continue to advance NeurAxons pipeline.
Deepa Pakianathan, Ph.D., general partner of Delphi Ventures, stated, NeurAxons lead candidate, NXN-188, is designed to provide migraine relief through a dual mechanism of action, and we are encouraged by the early indications that this approach may provide significant improvements over current migraine treatments. This is especially meaningful in a disorder with a current market opportunity of over $3 billion while present treatments provide relief only to a minority of patients.
We believe that NeurAxons leadership in nNOS science will translate into pain drugs that target novel mechanisms with the potential to improve upon the standard of care in multiple significant pain indications, added Samuel P. Wertheimer, Ph.D., principal of OrbiMed Advisors, LLC.
NeurAxon Inc. is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
For more information, please visit www.neuraxon.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility